On this episode of Translating Proteomics, Parag, Andreas, and special guest Don Kirkpatrick answer questions submitted by the Translating Proteomics community. They cover:
- Needs in plasma proteomics
- How proteomics impacts drug development – with special guest Don Kirkpatrick, Ph.D.!
- How lifestyle impacts the proteome
- How the Nautilus Proteome Analysis Platform is impacting tau and Alzheimer’s disease research
ReferencesShome et al., 2022 - Serum autoantibodyome reveals that healthy individuals share common autoantibodies
https://www.sciencedirect.com/science/article/pii/S2211124722006489
LaBaer Lab paper investigating autoantibody levels in plasma and their relationship to health.
Sylman et al., 2018 - A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients
https://www.nature.com/articles/s41598-018-25019-1
Mallick lab paper investigating temporal changes in platelets and their associations with cancer biology.
Krönke et al., 2014 - Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells
https://www.science.org/doi/10.1126/science.1244851
Seminal paper describing selective protein degradation caused by lenalidomide.
Fink and Ebert 2015 - The novel mechanism of lenalidomide activity
https://ashpublications.org/blood/article/126/21/2366/34644/The-novel-mechanism-of-lenalidomide-activity
Review of research elucidating the mechanisms of lenalidomide activity
Ndoja et al., 2025 - COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
https://www.mdpi.com/2073-4409/14/13/975
Describe links between kinase inhibitor vemurafenib and changes in ETV transcription factor degradation
Song et al., 2022 - RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
https://aacrjournals.org/cancerdiscovery/article/12/1/204/675622/RTK-Dependent-Inducible-Degradation-of-Mutant-PI3K
Use proteomics to discover that inavolisib acts through selective degradation of mutant PI3Kα
Canon et al., 2019 - The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
https://www.nature.com/articles/s41586-019-1694-1
Covers the development of an inhibitor of KRAS mutant KRAS (G12C).
Schneider et al., 2024 - Feeding gut microbes to nourish the brain: unravelling the diet-microbiota-gut-brain axis
https://www.nature.com/articles/s42255-024-01108-6
Review on the gut-brain axis
Webpage for Johanna Lampe’s Lab at Fred Hutch Cancer Center